ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
18 Oct 2021 10:45

Hong Kong Connect Flows: Tencent, Meituan, Wuxi Biologics, Kintor

We highlight Hong Kong Connect inflows into Tencent Holdings Limited (700 HK), Meituan (3690 HK),  and outflows from Wuxi Biologics (2269 HK).

Logo
188 Views
Share
30 Sep 2021 14:44

MicroPort MedBot Pre-IPO - RoboDoc - PHIP Updates and a Look at Its Largest Competitor

MicroPort MedBot, a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO. It is a subsidiary of Microport Scientific (853 HK)...

Logo
290 Views
Share
20 Sep 2021 10:29

Hong Kong Connect Flows: Tencent, HKEx, CNOOC

We will highlight weekly southbound connect inflows into Tencent (700 HK), HKEx (388 HK), Cnooc (883 HK) as well as outflows from Wuxi Biologics...

Logo
182 Views
Share
14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
167 Views
Share
08 Sep 2021 18:48

Novotech Health IPO: Valuation First-Look

Novotech is pre-marketing an HKEx IPO to raise $0.5-1.0 billion. In this note, we present our forecasts and take the first look at Novotech's...

Logo
277 Views
Share
x